Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | For the three months ended / March 31, 2026 | For the three months ended / March 31, 2025 |
|---|---|---|
| Total cost of sales | 9,531 | 7,421 |
| Gross profit | 14,735 | 9,861 |
| Operating expenses: | ||
| Research and development | 1,875 | 1,161 |
| General and administrative | 10,446 | 9,170 |
| Total operating expenses | 12,321 | 10,331 |
| Income (loss) from operations | 2,414 | (470) |
| Other expense: |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s R&D?
- Eton Pharmaceuticals, Inc. (ETON) reported R&D of $1.88M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s R&D changed year-over-year?
- Eton Pharmaceuticals, Inc.'s R&D increased by 61.5% year-over-year, from $1.16M to $1.88M.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s R&D?
- Over 3 years (2021 to 2025), Eton Pharmaceuticals, Inc.'s R&D has grown at a 7.6% compound annual growth rate (CAGR), from $6.24M to $7.77M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Eton Pharmaceuticals, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude